Effect of resveratrol on periodontal disease in an aging adult population

Effect of resveratrol on markers of oxidative stress and chronic inflammation and the clinical course of periodontal disease in an aging adult population

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN10684944

Enrollment

Registered

2025-04-21

Start date

2022-08-15

Completion date

Unknown

Last updated

2025-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment of periodontal disease in an aging adult population Oral Health

Interventions

All participants will be given a prophylaxis and will be randomly assigned to two study groups: i) the experimental group, which will receive a capsule with 500 mg of resveratrol every 12 hours, daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. People aged 45 to 59 years 2. Residence in Mexico City 3. Clinical diagnosis of periodontal disease 4. The patient must sign (or fingerprint) the informed consent letter.

Exclusion criteria

Exclusion criteria: 1. No occlusal trauma 2. No complete edentulousness 3. No smoking 4. No alcoholism 5. No antioxidant intake 6. No hormone replacement therapy

Design outcomes

Primary

Measure	Time frame
1. The effect of resveratrol on the clinical course of PD will be assessed by periodontal pocket depth, gingival index, and radiographs in aging adults with periodontal disease, at baseline, 3 and 6 months. 2. The effect of resveratrol on blood concentration of oxidative stress markers through measurement of isoprostanes, DNA damage, total antioxidant activity and the antioxidant capacity of the enzymes superoxide dismutase (SOD) and glutathione peroxidase (GPx) in adults with periodontal disease in the process of aging, at baseline, 3 and 6 months. 3. The effect of resveratrol on blood concentration of chronic inflammation markers through measurement of IL-1ß, IL-6, IL-8, IL-10, IL-12p70 and TNF-a in an aging adult population with periodontal disease, at baseline, 3 and 6 months.	—

Measure

Time frame

1. The effect of resveratrol on the clinical course of PD will be assessed by periodontal pocket depth, gingival index, and radiographs in aging adults with periodontal disease, at baseline, 3 and 6 months. 2. The effect of resveratrol on blood concentration of oxidative stress markers through measurement of isoprostanes, DNA damage, total antioxidant activity and the antioxidant capacity of the enzymes superoxide dismutase (SOD) and glutathione peroxidase (GPx) in adults with periodontal disease in the process of aging, at baseline, 3 and 6 months. 3. The effect of resveratrol on blood concentration of chronic inflammation markers through measurement of IL-1ß, IL-6, IL-8, IL-10, IL-12p70 and TNF-a in an aging adult population with periodontal disease, at baseline, 3 and 6 months.

—

Secondary

Measure	Time frame
Measured using on automated equipment (Selectra Junior) and commercial kits will be used (Randox Laboratories Ltd.) at baseline, 3 and 6 months: 1. Fasting glucose 2. Glycosylated hemoglobin 3. Lipid profile (total cholesterol, triglycerides and HDL cholesterol) 4. Renal profile (urea, uric acid and creatinine)	—

Countries

Mexico

Contacts

Public ContactBeatriz Hernández-Monjaraz

beatrizhmonjaraz@comunidad.unam.mx+52 5556230700 Ext. 39182

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026